June 19, 2024 09:22 AM EDT

Samsung Bio and Baxter dial up manufacturing deal to $223M

Anna Brown

News Reporter

Baxter Healthcare will pay Samsung Biologics an extra $208 million to manufacture certain drug products until the end of 2034 in a revised manufacturing contract …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Samsung Bio and Baxter dial up manufacturing deal to $223M

Anna Brown

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Versant unveils Light Horse with $62M and a partnership with Novartis

After lackluster 2024, biopharma industry prays stalled M&A will finally move into gear

Coave raises €32M Series A despite being two years away from the clinic

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

Sam­sung Bio and Bax­ter di­al up man­u­fac­tur­ing deal to $223M

News Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Samsung Bio and Baxter dial up manufacturing deal to $223M